Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
REVB
REVB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
REVB News
Revelation Biosciences Executes Third Reverse Stock Split in a Year
Jan 26 2026
stocktwits
Revelation Biosciences (REVB) Secures FDA Agreement for Gemini Drug's Clinical Trial Pathway
Jan 23 2026
NASDAQ.COM
Ericsson (ERIC) Reports Q4 Earnings Beat, Shares Surge 7.1%
Jan 23 2026
Benzinga
U.S. GDP Grows 4.4% as Trump Withdraws Tariffs on EU
Jan 23 2026
Benzinga
Revelation Biosciences (NASDAQ:REVB) Gains 25.22% After FDA Approval Pathway Agreement for Gemini Drug
Jan 23 2026
Benzinga
Revelation Biosciences (REVB) to Present Kidney Disease Treatment Data at Conference
Jan 15 2026
NASDAQ.COM
RevBio Receives FDA Approval for TETRANITE Clinical Trial
Dec 22 2025
Businesswire
Revelation Biosciences Submits FDA Meeting Package for Gemini AKI Treatment
Nov 24 2025
Newsfilter
Revelation Set to Meet with FDA Later This Year
Nov 20 2025
Yahoo Finance
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025
Aug 08 2025
Newsfilter
Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study
Jul 16 2025
Newsfilter
Upcoming Stock Splits This Week (July 7 to July 11) – Stay Invested
Jul 06 2025
TipRanks
US Stocks Likely To Open Higher: S&P 500 Sees 'Average Gain Of 6.1%' In 2nd Half, Expert Says
Jul 02 2025
Benzinga
Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025
Jul 01 2025
Newsfilter
Why Credo Technology Group Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
Jun 03 2025
Benzinga
Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering
May 29 2025
Newsfilter
Show More News
